Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Pharmaceutical Contract Development and Manufacturing Organization Market: By Service, By End User and Geography
Pharmaceutical Contract Development and Manufacturing Organization Market: By Service, By End User and Geography
Pharmaceutical Contract Development And Manufacturing Organization Market size was valued at 92.1 billion in 2022 and is expected to reach 145.0 million by 2029, at a CAGR of 6.7% from 2022 to 2028. Some of the key factors fueling the market growth include increasing investments in pharmaceutical R&D, advent of CDMO model into the outsourcing model, growing subcontracting volume by big pharmaceutical companies and rising healthcare standards in developing countries,. However, increasing lead time and logistics costs, stringent regulatory requirements and changing trade policies between countries are hindering the market growth. In addition, increasing outsourcing of clinical trials to emerging markets and growing focus on specialty medicines provides huge growth opportunity for the market.
The report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global pharmaceutical contract development and manufacturing organization market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities). Key stakeholders of the global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global pharmaceutical contract development and manufacturing organization (CDMO) products.
Study Period
2024-2030Base Year
2023CAGR
6.7%Largest Market
Asia-PacificFastest Growing Market
Asia-Pacific
As the population increases and the number of regional markets entering the global landscape continues to increase, drug companies are feeling pressure to bring drugs to market more rapidly. CDMO outsourcing remains a key strategy for easing the pressures of development. In particular, API manufacturing has kept a firm position as the most outsourced area for drug manufacturers. This has led to healthy growth related with the sector, which is likely to steadily rise, especially over the short term. Pharma companies often need to access specialised manufacturing resources, facilities and capabilities to progress a drug from development through to commercial production. The outsourcing landscape is very fragmented and highly competitive, with a wide range of full service and niche contract development and manufacturing organisations (CDMOs) to choose from, as well as pure play and embedded CDMOs. The embedded CDMO is a unique option within the pharma and biopharma outsourcing space.
Asia Pacific accounted for larger revenue share in global pharmaceutical contract development and manufacturing organization (CDMO) market with considerable CAGR. The growth in this region is due to growing incidences of chronic and lifestyle diseases, availability of expertise for clinical trials and increase in the outsourcing of research processes. Improving healthcare infrastructure and increasing favourable government initiatives are other factors responsible for market growth. China and India are the major contributors for the growth of the market in the region. North America held substantial market share during estimated period owing to increasing research activities by biotechnology companies and the rising demand for generics.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market CAGR |
6.7% |
|
By Service |
|
|
By End User |
|
Download Free Sample Report
The pharmaceutical cdmo market is projected to expand at a CAGR of 6.7% during the forecast period
Thermo Fisher Scientific Inc, Vetter Pharma International, Lonza Group, Recipharm AB, Catalent
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
Pharmaceutical Contract Development And Manufacturing Organization Market size was valued at 92.1 billion in 2022 and is expected to reach 145.0 million by 2029.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.